Home » News » R&D Trends » Codiak BioSciences names first executive team members

Codiak BioSciences names first executive team members

Tuesday, January 5, 2016

Codiak BioSciences today announced the first members of its core executive team: Ariel Jasie, Esq., chief business officer; Linda Bain, chief financial officer; and Konstantin Konstantinov, Ph.D., senior vice president of manufacturing and process sciences.

Codiak, a world-leading company in the field of exosome biology, recently closed the first portion of a planned $80 million-plus Series A and B financing. ARCH Venture Partners, Flagship Ventures, Fidelity Management & Research Co., the Alaska Permanent Fund and Alexandria Venture Investments are members of the funding syndicate. The company is establishing its headquarters in the Boston/Cambridge area and is expanding its R&D capabilities across its therapeutic and diagnostic programs.

Jasie joined Codiak from Celgene, where he led the strategy and operations group in the research and early development franchise. He previously served on Celgene’s business development team, leading numerous deals including M&A, in-licensing, collaborations, strategic equity investments, seeding, syndicating and constructing “build to buys,” and serving as board observer to certain collaboration partners/equity investments. He received his B.A. degree from the University of Maryland at College Park and his J.D. from Brooklyn Law School.

Bain, a certified public accountant, joined Codiak from Avalanche Biotechnologies where, as chief financial officer, she led a successful IPO and follow-on financing. She previously served as vice president of finance, business operations and treasurer at Bluebird Bio, where her tenure included a Series D financing and IPO. She also has held senior roles at Genzyme. Bain received her B.S. degree in accounting and business administration and an honors degree in accounting and business administration from the University of the Free State, South Africa.

Konstantinov, before joining Codiak, was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub. Previously, he worked for Bayer in Berkeley, Calif., for 14 years, advancing to the position of head of process sciences. He has published 60 peer-reviewed papers and has more than 15 patents and patent applications. Konstantinov received his Ph.D. in biochemical engineering from Osaka University, Japan, which was followed by postdoctoral work at DuPont and the University of Delaware.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!